Clinical relevance and predictors of anti-natalizumab antibodies in multiple sclerosis: A real-world retrospective cohort study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background Natalizumab is effective for relapsing MS but may trigger anti-natalizumab antibodies (ANZ) that neutralise drug activity and increase reactions. Trials report persistent antibodies in ∼6% and overall prevalence between 4% and 14%, but real-world burden and optimal testing remain uncertain. We assessed ANZ prevalence, timing, and correlates, comparing systematic with indication-driven testing. Methods Single-centre retrospective cohort of natalizumab-treated patients with ≥1 ANZ test. Testing followed routine care: systematic screening at months 6/12/18 or testing triggered by suspected inefficacy or infusion reactions. Clinical/MRI data were abstracted; time to positivity was used in Kaplan–Meier; predictors were assessed using multivariable logistic regression. Results Among 182 patients (348 tests), ANZ were detected in nine (4.9%; four persistent and five transient), all within the first 12 infusions. Positivity differed by indication ( p = 0.005): suspected inefficacy 10.5% (4/38), systematic screening 1.6% (5/304), post-reaction testing 0% (0/6). Within suspected inefficacy, MRI activity was more strongly associated with positivity than symptoms alone ( p = 0.04). In multivariable models, suspected inefficacy was the only independent predictor; adding indication improved discrimination (AUC 0.74 vs. 0.56). Conclusions In routine care, ANZ positivity is uncommon and occurs early. Indication-driven testing – especially when prompted by new MRI lesions – yields greater diagnostic value than routine screening of clinically stable patients, supporting a selective, context-driven approach to ANZ monitoring.
Fields of Study & Subjects
Multiple Sclerosis Research Studies
Monoclonal and Polyclonal Antibodies Research
Inflammatory Bowel Disease
Publication details
- Journal / source
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Volume
- 12
- Issue
- 1
- Pages
- 20552173261438267–20552173261438267
- Publication date
- 1 January 2026
- Language
- EN